CHU de Liege | CHR Citadel - Department of Gyneacology and Obstetrics
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The primary purpose of this study is to identify the recommended phase 2 dose (RP2D[s]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at the RP2D(s) selected and in disease subgroups in Part 2 (dose expansion).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
For participants with relapsed or refractory multiple myeloma:
For participants with previously treated AL amyloidosis:
Exclusion criteria
For participants with relapsed or refractory multiple myeloma:
For participants with previously treated AL amyloidosis:
Primary purpose
Allocation
Interventional model
Masking
195 participants in 2 patient groups
Loading...
Central trial contact
Study Contact
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal